ArticleArchives of endocrinology and metabolism2026
Treatment outcomes in patients with relapsed Graves' disease.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Relapsed Graves' disease: should continuous low-dose methimazole become a preferred strategy?Archives of endocrinology and metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to assess the outcomes of various treatment strategies in patients with relapsed Graves' disease (GD) after standard antithyroid drug therapy (ATD). The three treatment strategies evaluated were radioiodine therapy (RAI), continuous low-dose methimazole (MMI), and a second course of MMI. SUBJECTS AND
methodsThis was a retrospective cohort study of 330 patients with GD who received initial MMI therapy for 12 to 24 months, of whom 159 subsequently relapsed. The cohort was categorized into three groups: 39 patients received RAI therapy plus levothyroxine, 46 patients received continuous low-dose MMI, and 74 patients received a second course of MMI. The analysis included thyroid function monitoring, progression of thyroid eye disease (TED), quality-of-life measures, and changes in body weight during follow-up. Results: The group receiving continuous low-dose MMI had a longer period of euthyroidism compared with the other groups. The TED outcomes and body weight changes were similar across all groups. Quality of life did not differ significantly across groups. Notably, 45% of patients in the group receiving a second MMI course relapsed when MMI was discontinued after a mean treatment duration of approximately 42 months.
conclusionThe administration of continuous low-dose MMI is an alternative for managing patients with relapsed GD, particularly for those who prefer to avoid definitive treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.